{"id":"W3027850675","doi":"10.1016/j.cllc.2020.05.015","title":"Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Takeda Canada; Genentech; Meso Scale Diagnostics; Clovis Oncology; Chugai Pharmaceutical; Roche; Novartis; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AstraZeneca France; Takeda Pharmaceutical Company","keywords":"Crizotinib; Osimertinib; Medicine; Epidermal growth factor receptor; Lung cancer; Adenocarcinoma; Cancer research; Gefitinib; Tyrosine kinase; Oncology; Acquired resistance; Internal medicine; Erlotinib; Receptor; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003382155,0.0002262332,0.0005874925,0.00007881758,0.000102993,0.00005180163,0.00005862125,0.0001335,0.0001272855],"category_scores_gemma":[0.0002928743,0.0001878729,0.00008998023,0.0004818955,0.0001466581,0.0001903907,0.00005015925,0.0004258116,0.000004440396],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002763894,"about_ca_system_score_gemma":0.0004897175,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002945727,"about_ca_topic_score_gemma":0.00007603401,"domain_scores_codex":[0.9977376,0.0000884926,0.0008683092,0.0007284062,0.0002829339,0.0002941992],"domain_scores_gemma":[0.9986412,0.0002117017,0.0002977486,0.0003001594,0.0001827886,0.0003664225],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006494393,0.0001885402,0.9911438,0.0002376602,0.0004416211,0.0008319088,0.001026247,0.00005038691,0.0003714329,0.0004560282,0.001573308,0.003029679],"study_design_scores_gemma":[0.01162983,0.001115645,0.9766054,0.001049939,0.001777043,0.0001823674,0.0005035157,0.002888417,0.0005593731,0.00004903332,0.003260822,0.0003786591],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.983928,0.003236041,0.0007240027,0.008574137,0.0002563346,0.001169172,0.00003846183,0.0001468356,0.001927004],"genre_scores_gemma":[0.9943612,0.0002372379,0.001721632,0.00257957,0.0003623034,0.0002829396,0.0001812542,0.00004823356,0.0002256365],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01453839,"threshold_uncertainty_score":0.7661235,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05111740777455702,"score_gpt":0.4146171040608322,"score_spread":0.3634996962862752,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}